Structural highlights
Publication Abstract from PubMed
The Plasmodium falciparum PfA-M1 and PfA-M17 metalloaminopeptidases are validated drug targets for the discovery of antimalarial agents. In order to identify dual inhibitors of both proteins, we developed a hierarchical virtual screening approach, followed by in vitro evaluation of the highest scoring hits. Starting from the ZINC database of purchasable compounds, sequential 3D-pharmacophore and molecular docking steps were applied to filter the virtual 'hits'. At the end of virtual screening, 12 compounds were chosen and tested against the in vitro aminopeptidase activity of both PfA-M1 and PfA-M17. Two molecules showed significant inhibitory activity (low micromolar/nanomolar range) against both proteins. Finally, the crystal structure of the most potent compound in complex with both PfA-M1 and PfA-M17 was solved, revealing the binding mode and validating our computational approach.
Identification and Validation of a Potent Dual Inhibitor of the P. falciparum M1 and M17 Aminopeptidases Using Virtual Screening.,Ruggeri C, Drinkwater N, Sivaraman KK, Bamert RS, McGowan S, Paiardini A PLoS One. 2015 Sep 25;10(9):e0138957. doi: 10.1371/journal.pone.0138957., eCollection 2015. PMID:26406322[1]
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
References
- ↑ Ruggeri C, Drinkwater N, Sivaraman KK, Bamert RS, McGowan S, Paiardini A. Identification and Validation of a Potent Dual Inhibitor of the P. falciparum M1 and M17 Aminopeptidases Using Virtual Screening. PLoS One. 2015 Sep 25;10(9):e0138957. doi: 10.1371/journal.pone.0138957., eCollection 2015. PMID:26406322 doi:http://dx.doi.org/10.1371/journal.pone.0138957
